A Phase I/II Randomized Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Latest Information Update: 31 Mar 2023
At a glance
- Drugs Cancer vaccine (Primary) ; Cancer vaccine (Primary) ; Rintatolimod (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 18 Oct 2021 Status changed from completed to discontinued.
- 07 Apr 2020 Status changed from active, no longer recruiting to completed.
- 26 Sep 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.